0001493152-24-019999.txt : 20240515 0001493152-24-019999.hdr.sgml : 20240515 20240515171209 ACCESSION NUMBER: 0001493152-24-019999 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GlucoTrack, Inc. CENTRAL INDEX KEY: 0001506983 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 980668934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41141 FILM NUMBER: 24952497 BUSINESS ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 BUSINESS PHONE: 972 (8) 675-7878 MAIL ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 FORMER COMPANY: FORMER CONFORMED NAME: Integrity Applications, Inc. DATE OF NAME CHANGE: 20101203 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________________ to ________________

Commission File Number: 001-41141

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware		98-0668934
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

301 Route 17 North, Suite 800 Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

(201) 842-7715

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐		Accelerated filer ☐
	Non-accelerated filer ☒		Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 14, 2024, 27,393,002 shares of the Company’s common stock, par value $0.001 per share, were outstanding.

GLUCOTRACK INC.

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION		4
Item 1. Financial Statements.		4
Condensed Consolidated Balance Sheets		4
Condensed Consolidated Statements of Operations and Comprehensive Loss		5
Condensed Consolidated Statement of Changes in Stockholders’ Equity		6
Condensed Consolidated Statements of Cash Flows		7
Notes to Condensed Consolidated Financial Statements		8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		15
Item 3. Quantitative and Qualitative Disclosures About Market Risk.		19
Item 4. Controls and Procedures.		19
PART II - OTHER INFORMATION		20
Item 1. Legal Proceedings		20
Item 1A Risk Factors		20
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		20
Item 3. Defaults Upon Senior Securities		20
Item 4. Mine Safety Disclosures		20
Item 5. Other Information		20
Item 6. Exhibits.		20
EXHIBIT INDEX		20
SIGNATURES		21

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “plan,” “may,” “will,” “could,” “would,” “should” and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified in our Annual Report on Form 10-K for year ended December 31, 2023, under the caption “Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this report unless required by law.

GLUCOTRACK INC.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

GLUCOTRACK INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands of US dollars except share data)


	In thousands of US dollars (except stock data)
	March 31, 2024			December 31, 2023
	Unaudited

Current Assets
Cash and cash equivalents		1,497			4,492
Other current assets		440			376
Total current assets		1,937			4,868

Operating lease right-of-use asset, net (Note 3C)		77			-
Property and equipment, net		82			27
Restricted cash		10			10
TOTAL ASSETS		2,106			4,905

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable		1,014			839
Operating lease liability, current (Note 3C)		24			-
Other current liabilities		444			673
Total current liabilities		1,482			1,512

Non-current Liabilities
Loans from stockholders		195			196
Operating lease liability, non-current (Note 3C)		53			-
Total liabilities		1,730			1,708

Commitments and contingent liabilities (Note 4)		-			-

Stockholders’ Equity
Common Stock of $ 0.001 par value (“Common Stock”):
500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		27			20
Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		27			20
Additional paid-in capital		113,029			112,966
Receipts on account of shares		78			48
Accumulated other comprehensive income		22			16
Accumulated deficit		(112,780	)		(109,853	)
Total stockholders’ equity		376			3,197

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		2,106			4,905

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

GLUCOTRACK INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands of US dollars except share data) (unaudited)

	2024			2023
	Three-month period ended March 31,
	2024			2023

Research and development	$	2,148		$	642
General and administrative		733			642
Selling and marketing expenses		70			-
Total operating expenses		2,951			1,284

Operating loss		2,951			1,284

Finance expenses (income), net		(24	)		2

Net Loss		2,927			1,286
Other comprehensive income:
Foreign currency translation adjustment		(6	)		(5	)

Comprehensive loss for the period	$	2,921		$	1,281

Basic and diluted net loss per common stock	$	(0.12	)	$	(0.08	)

Weighted average number of common stock used in computing basic and diluted loss per common stock		24,959,768			15,503,632

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

GLUCOTRACK INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands of US Dollars except share data) (unaudited)

	Numbers of Shares		Amount		Paid-in Capital			account of shares			Comprehensive Income		Accumulated Deficit			Stockholders’ Equity
	In thousands of US Dollars (except share data)
	Common Stock				Additional			Receipts on			Accumulated Other					Total
	Numbers of Shares		Amount		Paid-in Capital			account of shares			Comprehensive Income		Accumulated Deficit			Stockholders’ Equity

Balance as of January 1, 2023		15,500,730		15		103,095			4			17		(101,901	)		1,230
Loss for the period		-		-		-			-			-		(1,286	)		(1,286	)
Other comprehensive income		-		-		-			-			5		-			5
Stock-based compensation		-		-		57			-			-		-			57
Issuance of restricted shares as compensation towards directors		2,902		(*) -		4			(4	)		-		-			-
Restricted shares to be issued as compensation towards directors		-		-		-			5			-		-			5
Balance as of March 31, 2023		15,503,632		15		103,156			5			22		(103,187	)		11

Balance as of January 1, 2024		20,892,193		20		112,966			48			16		(109,853	)		3,197
Balance		20,892,193		20		112,966			48			16		(109,853	)		3,197
Loss for the period		-		-		-			-			-		(2,927	)		(2,927	)
Other comprehensive income		-		-		-			-			6		-			6
Stock-based compensation		-		-		22			-			-		-			22
Issuance of restricted shares as compensation towards directors		194,503		-		48			(48	)		-		-			-
Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement (Note 4B)		100,000		1		(1	)		-			-		-			-
Restricted shares to be issued as compensation towards directors		-		-		-			78			-		-			78
Exercise of prefunded warrants into shares (Note 3A)		1,976,470		2		(2	)		-			-		-			-
Exchange of warrants into shares (Note 3B)		3,593,203		4		(4	)		-			-		-			-
Balance as of March 31, 2024		26,756,369		27		113,029			78			22		(112,780	)		376
Balance		26,756,369		27		113,029			78			22		(112,780	)		376

(*)	Represents amount lower than $1.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

GLUCOTRACK INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands of US Dollars)

	2024			2023
	Three-month period ended March 31,
	2024			2023
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period	$	(2,927	)	$	(1,286	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4			4
Stock-based compensation		22			57
Issuance of restricted shares as compensation towards directors		78			5
Linkage difference on principal of loans from stockholders		(1	)		2
Changes in assets and liabilities:
Increase in other current assets		(64	)		(137	)
Increase (decrease) in accounts payable		175			(13	)
Increase (Decrease) in other current liabilities		(229	)		55
Net cash used in operating activities		(2,942	)		(1,313	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(59	)		-
Net cash used in investing activities		(59	)		-

Effect of exchange rate changes on cash and cash equivalents, and restricted cash		6			(5	)

Change in cash and cash equivalents, and restricted cash		(2,995	)		(1,318	)

Cash and cash equivalents, and restricted cash at beginning of the period		4,502			2,331

Cash and cash equivalents, and restricted cash, end of period	$	1,507		$	1,013

	Three-month period ended March 31,
	2024		2023
	(Unaudited)
Supplemental disclosure of cash flow activities:

(a) Net cash paid during the year for:

Interest	$	28	$	-

(b) Non-cash activities:

Recognition of right for usage asset against a lease liability	$	79	$	-

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 1 – GENERAL

A.	Glucotrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes. The Company is currently developing an Implantable Continuous Blood Glucose Monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM Product”).

B.	Liquidity and capital resources

	To date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are expected to require substantial additional expenditures. Therefore, the Company is dependent upon external sources for financing its operations. As of March 31, 2024, the Company has incurred accumulated deficit of $112,780. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods. As of March 31, 2024, the balance of cash and cash equivalents which amounted to $1,497,000 is insufficient for the Company to realize its business plans for the twelve-month period subsequent to the reporting period.

	Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	During the year ended December 31, 2023, the Company raised net proceeds of $8,730 through completion of an underwritten public offering. In addition, during the year ended December 31, 2023, the Company entered into exchange agreement with certain shareholders under which warrants with down round protection feature have been exchanged into shares of common stock in order to improve its equity structure to enable the completion of a planned equity financing (see also Note 3A). Moreover, in April 2024, the Company raised net proceeds of $500,000 through completion of private placement transaction (see also Note 5A). The Company plans to finance its operations through the sale of equity and/or debt securities (including shelf registration statement on Form S-3 that was declared effective on September 27, 2021 by the Securities and Exchange Commission (“SEC”) and which allows the Company to register up to $90,000 of certain equity and/or debt securities of the Company through prospectus supplement). There can be no assurance that the Company will succeed in obtaining the necessary financing or generating sufficient revenues from sales of its Glucotrack CBGM Product, if any, in order to continue its operations as a going concern. The condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Basis of Presentation

	The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the SEC on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

	The results for the period of three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

B. Use of Estimates in the Preparation of Financial Statements

The preparation of the condensed interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. Management believes that there are no critical accounting estimates in these financial statements.

C. Principles of Consolidation

The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

D. Cash and Cash Equivalents

Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from the date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.

E. Leases

The Company applies ASC Topic 842, “Leases” (“ASC 842”) under which the Company determines if an arrangement is a lease at inception. The Company’s assessment is based on: (i) whether the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the asset.

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases.

Right of Usage (“ROU”) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company’s leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (“IBR”) based on the information available on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment - Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

F. Modification of equity-classified contracts

The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange), if any, is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified instrument are not reflected in accumulated deficit. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share.

G. Basic and diluted loss per share

Basic loss per share is computed by dividing the loss for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding.

In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method,” if the effect of each of such financial instruments is dilutive.

In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants.

Shares that will be issued upon the exercise of all stock options and stock warrants (other than pre-funded warrants), have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)

(in thousands of US Dollars)

NOTE 3 - SIGNIFICANT TRANSACTIONS

A.	Exercise of pre-funded warrants

	On January 3, 2024, a number of 1,976,470 pre-funded warrants granted through underwritten public offering in April 2023 have been fully exercised into the same number of shares of Common Stock of the Company.

B.	Exchange Agreement

	On February 13, 2024, the Company entered into an Exchange Agreement with certain warrantholders (the “Holders”), pursuant to which the Company and the Holders agreed to exchange (the “Exchange”) warrants with down round protection feature exercisable to common shares (the “Warrants”) owned by the Holders for shares of Common Stock to be issued by the Company.

	On February 13, 2024, the Company closed the Exchange and issued to the Holders on February 15, 2024 an aggregate of 3,593,203 shares of Common Stock in exchange for 4,381,953 Warrants (the “Shares”).

	It was also agreed that the Holders will not, during the period (“Lock-Up Period”) (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided however that the Holder, during the Lock-Up Period, may (a) sell or contract to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than $0.80 per Share on any trading day with no limitation on volume. The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $1.00 per Share for five consecutive trading days. The Company accounted for the Exchange of the aforesaid warrants as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not recorded.

C.	Lease Agreement

	On February 19, 2024, the Company entered into Lease Agreement (the “Agreement”) with Tapsak Enterprises LLC dba Virginia Analytical (the “Landlord”) under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of $2.5 over a period of 3-years commencing March 1, 2024 through February 28, 2027 (the “Initial Lease Period”). A security deposit of $2.5 which represents a one month payment is held by the Landlord and will be returned to the Company at the end of the Initial Lease Period.

	In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the “Option Term”), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate which is determined as the comparable cost for similar property in the Front Royal, Virginia area.

	In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to usage asset equals to lease liability in total amount of $79. The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the estimated interest rate that the Company would be required to pay in order to borrow a similar amount for a similar period in order to obtain a similar amount on the date of first recognition of the lease (using a discount rate of 9.03%). As part of the lease term, the Company considered only the Initial Lease Period, as the exercise of the option to extend the period was not considered as reasonably certain.

Right of usage asset:

SCHEDULE OF RIGHT OF USAGE ASSET

	Premises
Cost
Balance as of January 1, 2024		-
Additions		79
Balance as of March 31, 2024		79
Accumulated amortization
Balance as of January 1, 2024		-
Additions		2
Balance as of March 31, 2024		2

Amortized cost as of March 31, 2024		77

Lease liability:

SCHEDULE OF LEASE LIABILITY

	Premises

Balance as of January 1, 2024		-
Additions		79
Interest expenses		1
Lease payments		(3	)

Balance as of March 31, 2024		77

Amounts recognized in statements of cash flow:

	Three months period ended March 31, 2024

Amortization of the right for usage asset		2
Interest expense in respect of lease liability		1
Repayment of principal in respect of lease liability		3

Total negative cash flows in respect of leasing for the period of three months ended March 31, 2024 are approximately $3.

Analysis of contractual payment dates of lease liability as of March 31, 2024:


Up to a year	$	30
Between 1-2 years		30
More than 2 years		28
Total (undiscounted)	$	88

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)

(in thousands of US Dollars)

NOTE 4 – COMMITMENTS AND CONTINGENT LIABILITIES

	A.	On March 4, 2004, the IIA provided Integrity Israel with a grant of approximately $93 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the “Development Plan”). Integrity Israel is required to pay royalties to the IIA at a rate ranging between 3-5% of the proceeds from the sale of the Company’s products arising from the Development Plan up to an amount equal to $93 plus interest at LIBOR from the date of grant. As to the replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of March 31, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $73 excluding interest. Such contingent obligation has no expiration date.

	B.	On October 7, 2022 (“the Closing Date”), the Company entered into an Intellectual Property Purchase Agreement (the “Agreement”) with Paul Goode, the Company’s Chief Executive Officer (the “Seller”), under which the parties agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, the Seller shall sell, assign, transfer, convey and deliver to the Company, all of the Seller’s right, title and interest in and to the following assets, properties and rights (collectively, the “Purchased Assets”):

	(a)	All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the “Conveyed Intellectual Property”); and

	(b)	All the goodwill relating to the Purchased Assets.

In consideration for the sale by the Seller of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated the Company to issue up to 1,000,000 shares of its Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the “Purchase Price”). In addition, if upon the final issuance, the aggregate 1,000,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the “True-Up Shares”). All shares of Common Stock of the Company that will be issued under this agreement shall be (i) restricted over a limited period of 1-year and issued in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and (ii) subject to the lockup provisions.

When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such as when there is no substantive process in the acquired entity) the transaction is accounted for as an asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (“IPR&D”) to be used in research and development projects which have been determined not to have alternative future use, is expensed immediately.

At the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as a contingent event outside the Company’s control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period of time. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved, or when it will be considered as reasonably estimable under ASC 450, Contingencies.

During June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance milestone the Company was committed to issue 100,000 restricted shares to the Seller. Accordingly, in 2023, the Company recorded an amount of $131 as research and development expenses with a similar amount as an increase to additional paid-in capital. The shares were issued on February 6, 2024. As of March 31, 2024, the achievement of all other remaining performance milestones was not considered probable and thus nothing was accrued with respect to thereof.

NOTE 5 - SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued May 15, 2024. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, except as follows:

A.	Private Placement Agreement

On April 22, 2024, the Company entered into private placement agreement under which the Company issued 396,825 shares of its common stock at a price of $1.26 per share for aggregate gross proceeds of $500,000 (the “Offering”). The Offering included the participation of certain members of the Company’s executive management, Board of Directors and existing shareholders.

There were no warrants issued and no commissions or brokerage fees paid in connection with the Offering.

B.	Reverse Stock Split

As of the date of the filing of this Quarterly Report on 10-Q, the Company has not filed the Certificate of Amendment to implement the Reverse Stock Split, and the Reverse Stock Split is not effective as of the time of filing.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, capital raising and financing, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “may,” “will,” “could,” “would,” “should” and other similar words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under the caption “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2023. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q.

Overview

We are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes. We are currently developing an implantable (“CBGM”) for those with Type 1 diabetes and insulin-dependent Type 2 diabetes.

The Company was founded with a mission to develop GlucoTrack®, a non-invasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation of GlucoTrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto one’s earlobe. A limited release beta test in Europe and the Middle East demonstrated the need for an updated product with improved accuracy and human factors. As the glucose monitoring landscape rapidly moved away from point-in-time measurement to continuous measurement since then, the Company recently determined that it would focus its efforts on developing its Implantable CBGM. As such, we have since withdrawn our CE Mark for GlucoTrack and are no longer pursuing commercialization of this product or development of any further iterations.

The Company is currently developing an implantable CBGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. Implant longevity is key to the success of such a device. We have recently completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the current sensor design. We have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality. The Company will initiate a long-term animal trial in late Q4 2024 as well as initiate development of its commercial device, also in late Q4, in preparation of regulatory submission in late 2024 for a first in human study. We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.

We are currently developing our own mobile companion application and a cloud-based solution platform to provide real time, data driven personalized tools to effectively help users manage their diabetes. In addition to being a critical and effective management tool for the end user, we believe that third parties such as insurers, pharmaceutical companies and advertisers would be willing to pay for the de-identified data that we will obtain through our platform, and that this is an opportunity for us to develop an additional revenue source.

Our Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at Dexcom and MiniMed, CFO, James Cardwell, CPA who has over 16 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance, James P. Thrower PhD, Vice President of Engineering, a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and Dexcom, Inc., Mark Tapsak PhD, Vice President of Sensor Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles at Dexcom and Medtronic, and Drinda Benjamin, Vice President of Marketing, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles at Intuity Medical, Senseionics, Abbott Diabetes, and Medtronic Diabetes. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., Dr. Alexander Raykhman PhD, a measurement and artificial intelligence expert and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company.

Recent Events

As previously reported, on May 26, 2023, the Company received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company no longer complied with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Bid Price Rule”). Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company was provided with a compliance period of 180 calendar days, or until November 22, 2023, to regain compliance with the Bid Price Rule.

On November 24, 2023, the Company received a notice from Nasdaq stating that it has been granted an additional 180 calendar days, or until May 20, 2024, to regain compliance with the Bid Price Rule (the “Extended Compliance Period”). If at any time during the Extended Compliance Period, the closing bid price of our Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Nasdaq will provide written confirmation that we have regained compliance with the Bid Price Rule. If we cannot demonstrate compliance during the Extended Compliance Period, then Nasdaq will provide notice that our Common Stock will be subject to delisting. At that time, the Company may appeal the Staff’s determination to a hearings panel.

At the Company’s annual meeting of stockholders held on April 26, 2024, the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors (the “Board”) to file a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.001 per share at a ratio between 1-for-5 and 1-for-30, to be effected at such time and date, if at all, as determined by the Board in its sole discretion (the “Reverse Stock Split”). On April 30, 2024, the Board approved the Reverse Stock Split. Among other considerations, the Company plans to implement the Reverse Stock Split to satisfy the Bid Price Rule for continued listing on Nasdaq. There can be no assurance that we will be able to regain and sustain compliance with all applicable requirements for continued listing on Nasdaq. In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our common stock may be delisted from Nasdaq.

On February 13, 2024, the Company entered into an exchange agreement with certain shareholders (the “Holders”), pursuant to which the Company and the Holders agreed to exchange 4,381,953 of common stock purchase warrants owned by the Holders for 3,593,203 shares of the Company’s common stock, par value $0.001 per share.

The summary of our significant accounting policies is included under Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our fiscal 2023 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to the critical accounting policies and estimates as filed in such report.

Results of Operations

The following discussion of our operating results explains material changes in our results of operations for the three-months ended March 31, 2024 compared with the same periods ended March 31, 2023. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report.

Consolidated Results of Operations for the Three Months ended March 31, 2024 and 2023

Research and development expenses

Research and development expenses were approximately $2.1 million for the three-month period ended March 31, 2024, as compared to approximately $642,000 for the prior-year period. The increase is attributable to consulting fees we accrued during the period.

Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses. We expect research and development expenses to increase in 2024 and beyond, primarily due to hiring additional personnel, as well the development of Glucotrack CBGM; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new Glucotrack CBGM models and others.

Marketing expenses

Marketing expenses were approximately $70,000 for the three-month period ended March 31, 2024, as compared to $0 for the prior-year period. This increase is primarily attributable to business development personnel and professional marketing services.

General and administrative expenses

General and administrative expenses were approximately $733,000 for the three-month period ended March 31, 2024, as compared to approximately $642,000 for the prior-year period. The increase is attributable to professional fees we accrued during the period.

General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services.

Financing income (expenses), net

Financing income, net was approximately $24,000 for the three-month period ended March 31, 2024, as compared to financing expense of approximately $2,000 for the prior-year period. The increase is attributable to interest income received during the period.

Net Loss

Net loss was approximately $2.93 million for the three-month period ended March 31, 2024, as compared to approximately $1.31 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our research and development operating expenses, as described above.

Cash Flows for the Nine Months Ended March 31, 2024 and 2023

Operating Activities

Net cash used in operating activities was approximately $2.94 million and approximately $1.31 million for the three-month periods ended March 31, 2024 and 2023, respectively. Net cash used in operating activities primarily reflects the net loss for those periods of approximately $2.93 million and approximately $1.29 million, respectively.

Investing Activities

Net cash used in investing activities was $59,000 and $0 for the three-month periods ended March 31, 2024 and 2023, respectively. Net cash used in investing activities primarily reflects the purchasing of fixed assets.

Off-Balance Sheet Arrangements

As of March 31, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our condensed consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Liquidity and Capital Resources

To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities.

Since our incorporation, we have devoted substantially all our resources to research and product development and to providing general and administrative support for these activities. Since our incorporation, we have incurred significant losses and negative cash flows from operations. During the three months ended March 31, 2024, we incurred a net loss of approximately $3.0 million and used $2.9 million of cash in our operations. As of March 31, 2024, we had an accumulated deficit of approximately $112.8 million. We expect to continue to incur significant and increasing losses and do not expect positive cash flows from operations for the foreseeable future, and our net losses may fluctuate significantly from period to period depending on the timing of and expenditures on our research and development activities.

Based on our operating plans, we do not expect that our current cash and cash equivalents as of March 31, 2024, will be sufficient to fund our operating, investing, and financing cash flow needs for at least the next twelve months, assuming our programs advance as currently contemplated. Based upon this review and our current financial condition, the Company has concluded that substantial doubt exists as to our ability to continue as a going concern. We have and believe we will continue to be able to raise additional capital through debt financing, private or public equity financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. However, there can be no assurances that such financing will be available or will be at terms acceptable to us, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our clinical trials or other operations. If any of these events occur, our ability to achieve our operational goals would be adversely affected. Our future capital requirements and the adequacy of available funds will depend on many factors, including those described in the section titled “Risk Factors.” Depending on the severity and direct impact of these factors on us, we may be unable to secure additional financing to meet our operating requirements on commercially acceptable terms favorable to us, or at all.

Going Concern Uncertainty

As of December 31, 2023, cash on hand was $1,497,000. The development and commercialization of non-invasive glucose monitoring devices for use by people, are expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating cash flow and have a significant accumulated deficit. These factors raise substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. We plan to finance our operations through the sale of equity (including a shelf registration statement on Form S-3 that was declared effective on September 27, 2021 by the SEC which allows the Company to register up to $90,000 of certain equity and/or debt securities of the Company). There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations.

However, in April 2024, the Company raised net proceeds of $500,000 through the completion of a private placement transaction.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2024, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management, including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure, due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate financial reporting.

Management has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees and engaging in external financial reporting consultants. Management intends to implement procedures to remediate such material weaknesses during the fiscal year 2024; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal control over financial reporting.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. The outcome of litigation is inherently uncertain, and there can be no assurances that favorable outcomes will be obtained. In addition, regardless of the outcome, such proceedings or claims can have an adverse impact on us, which may be material because of defense and settlement costs, diversion of resources and other factors.

Item 1A. Risk Factors.

You should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report for the fiscal year ended December 31, 2023, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report for the fiscal year ended December 31, 2023, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. The risk factors set forth below supplements and updates the risk factors previously disclosed and should be read together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2023 and with any risk factors we may include in subsequent periodic filings with the SEC.

We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.

Given the current momentum for continuous blood glucose monitoring (“CBGM”) in the diabetes market, we have announced our decision to reset our priorities, improve our commercial outlook and refine our business strategy to focus on our implantable CBGM technology. Should our efforts to focus on this CBGM technology not be successful, we will need to further evaluate our business strategy and, as a result, our Board of Directors may decide that it is in the best interest of our stockholders to dissolve our Company and liquidate our assets or otherwise modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development, commercialization and manufacturing activities. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.

Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.

Our common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common stock on The Nasdaq Stock Market LLC.

As previously disclosed, on May 26, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

We initially had 180 days from May 26, 2023, or through November 22, 2023, to regain compliance with the Bid Price Rule. However, on November 24, 2023, we received a notice from Nasdaq stating that we were granted an additional 180 calendar days, or until May 20, 2024, to regain compliance with the Bid Price Rule (the “Extended Compliance Period”). If at any time during the Extended Compliance Period, the closing bid price of our Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that we have regained compliance with the Bid Price Rule. If we cannot demonstrate compliance during the Extended Compliance Period, then Nasdaq will provide notice that our Common Stock will be subject to delisting. At that time, the Company may appeal the Staff’s determination to a hearings panel.

There can be no assurance that we will be able to regain and sustain compliance with all applicable requirements for continued listing on Nasdaq. In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our common stock may be delisted from Nasdaq.

If our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) During the quarter ended March 31, 2024, there were no unregistered sales of our securities that were not reported in a Current Report on Form 8-K.

(b) Not applicable.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits.

Exhibit No.		Description
3.1		Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)
3.2		Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)
3.3		Bylaws of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1 filed with the SEC on August 22, 2011)
3.4		Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 23, 2020)
3.5		Amendments to The Company’s Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2022)
10.1†		Form of Exchange Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 16, 2024)
31.1**		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) or Rule 15d-14(a)
31.2**		Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) or Rule15d-14(a)
32.1*		Certification of Chief Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Chief Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Schema Document
101.CAL*		Inline XBRL Calculation Linkbase Document
101.LAB*		Inline XBRL Label Linkbase Document
101.PRE*		Inline XBRL Presentation Linkbase Document
101.DEF*		Inline XBRL Definition Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed herewith.
**	Furnished herewith.
†	Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 15, 2024

	GLUCOTRACK, INC.

	By:	/s/ James Cardwell
	Name:	James Cardwell
	Title	Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Paul Goode, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2024 of Glucotrack, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2024	By:	/s/ Paul Goode
		Paul Goode
		Principal Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, James Cardwell, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2024 of Glucotrack, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2024	By:	/s/ James Cardwell
		James Cardwell
		Principal Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the “Company”) for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Paul Goode
		Paul Goode
		Principal Executive Officer

	Dated: May 15, 2024

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the “Company”) for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Cardwell, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ James Cardwell
		James Cardwell
		Principal Financial Officer

	Dated: May 15, 2024

EX-101.SCH 6 gctk-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - GENERAL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SCHEDULE OF RIGHT OF USAGE ASSET (Details) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SCHEDULE OF LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gctk-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gctk-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 gctk-20240331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Sale of Stock [Axis] Private Placement [Member] Statistical Measurement [Axis] Maximum [Member] Prefunded Warrants [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exchange Agreement [Member] Lease Agreements [Member] Long-Lived Tangible Asset [Axis] Premises [Member] Lease Contractual Term [Axis] Up to a Year [Member] Between 1-2 Years [Member] More Than 2 Years [Member] Legal Entity of Counterparty, Type [Axis] Israeli Innovation Authority [Member] Minimum [Member] Legal Entity [Axis] Intellectual Property Purchase Agreement [Member] Class of Stock [Axis] Trueup Shares [Member] Private Placement Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Current Assets Cash and cash equivalents Other current assets Total current assets Operating lease right-of-use asset, net (Note 3C) Property and equipment, net Restricted cash TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Accounts payable Operating lease liability, current (Note 3C) Other current liabilities Total current liabilities Non-current Liabilities Loans from stockholders Operating lease liability, non-current (Note 3C) Total liabilities Commitments and contingent liabilities (Note 4) Stockholders’ Equity Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively Additional paid-in capital Receipts on account of shares Accumulated other comprehensive income Accumulated deficit Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development General and administrative Selling and marketing expenses Total operating expenses Operating loss Finance expenses (income), net Net Loss Other comprehensive income: Foreign currency translation adjustment Comprehensive loss for the period Basic net loss per common stock Diluted net loss per common stock Weighted average number of common stock outstanding used in computing basic net loss per share Weighted average number of common stock outstanding used in computing diluted net loss per share Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the period Other comprehensive income Stock-based compensation Issuance of restricted shares as compensation towards directors Issuance of restricted shares as compensation towards directors, shares Restricted shares to be issued as compensation towards directors Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement (Note 4B) Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement, shares Exercise of prefunded warrants into shares (Note 3A) Exercise of prefunded warrants into shares, shares Exchange of warrants into shares (Note 3B) Exchange of warrants into shares, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Issuance of restricted shares as compensation towards directors Linkage difference on principal of loans from stockholders Changes in assets and liabilities: Increase in other current assets Increase (decrease) in accounts payable Increase (Decrease) in other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash used in investing activities Effect of exchange rate changes on cash and cash equivalents, and restricted cash Change in cash and cash equivalents, and restricted cash Cash and cash equivalents, and restricted cash at beginning of the period Cash and cash equivalents, and restricted cash, end of period Supplemental disclosure of cash flow activities: Interest (b) Non-cash activities: Recognition of right for usage asset against a lease liability Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Transactions SIGNIFICANT TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENT LIABILITIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates in the Preparation of Financial Statements Principles of Consolidation Cash and Cash Equivalents Leases Modification of equity-classified contracts EX-101.PRE 10 gctk-20240331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41141
Entity Registrant Name	GLUCOTRACK, INC.
Entity Central Index Key	0001506983
Entity Tax Identification Number	98-0668934
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	301 Route 17 North
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	Rutherford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07070
City Area Code	(201)
Local Phone Number	842-7715
Title of 12(b) Security	Common Stock
Trading Symbol	GCTK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		27,393,002

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,497,000	$ 4,492,000
Other current assets	440,000	376,000
Total current assets	1,937,000	4,868,000
Operating lease right-of-use asset, net (Note 3C)	77,000
Property and equipment, net	82,000	27,000
Restricted cash	10,000	10,000
TOTAL ASSETS	2,106,000	4,905,000
Current Liabilities
Accounts payable	1,014,000	839,000
Operating lease liability, current (Note 3C)	24,000
Other current liabilities	444,000	673,000
Total current liabilities	1,482,000	1,512,000
Non-current Liabilities
Loans from stockholders	195,000	196,000
Operating lease liability, non-current (Note 3C)	53,000
Total liabilities	1,730,000	1,708,000
Commitments and contingent liabilities (Note 4)
Stockholders’ Equity
Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	27,000	20,000
Additional paid-in capital	113,029,000	112,966,000
Receipts on account of shares	78,000	48,000
Accumulated other comprehensive income	22,000	16,000
Accumulated deficit	(112,780,000)	(109,853,000)
Total stockholders’ equity	376,000	3,197,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,106,000	$ 4,905,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	26,756,369	20,892,193
Common stock, shares outstanding	26,756,369	20,892,193

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Research and development	$ 2,148	$ 642
General and administrative	733	642
Selling and marketing expenses	70
Total operating expenses	2,951	1,284
Operating loss	2,951	1,284
Finance expenses (income), net	(24)	2
Net Loss	2,927	1,286
Other comprehensive income:
Foreign currency translation adjustment	(6)	(5)
Comprehensive loss for the period	$ 2,921	$ 1,281
Basic net loss per common stock	$ (0.12)	$ (0.08)
Diluted net loss per common stock	$ (0.12)	$ (0.08)
Weighted average number of common stock outstanding used in computing basic net loss per share	24,959,768	15,503,632
Weighted average number of common stock outstanding used in computing diluted net loss per share	24,959,768	15,503,632

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)

Common Stock [Member]

Additional Paid-in Capital [Member]

Receipts on Account of Shares [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Total

Balance at Dec. 31, 2022

$ 15,000

$ 103,095,000

$ 4,000

$ 17,000

$ (101,901,000)

$ 1,230,000

Balance, shares at Dec. 31, 2022

15,500,730

Loss for the period

(1,286,000)

Other comprehensive income

5,000

Stock-based compensation

57,000

Issuance of restricted shares as compensation towards directors

^[1]

4,000

(4,000)

Issuance of restricted shares as compensation towards directors, shares

2,902

Restricted shares to be issued as compensation towards directors

5,000

Balance at Mar. 31, 2023

$ 15,000

103,156,000

5,000

22,000

(103,187,000)

11,000

Balance, shares at Mar. 31, 2023

15,503,632

Balance at Dec. 31, 2023

$ 20,000

112,966,000

48,000

16,000

(109,853,000)

3,197,000

Balance, shares at Dec. 31, 2023

20,892,193

Loss for the period

(2,927,000)

Other comprehensive income

6,000

Stock-based compensation

22,000

Issuance of restricted shares as compensation towards directors

48,000

(48,000)

Issuance of restricted shares as compensation towards directors, shares

194,503

Restricted shares to be issued as compensation towards directors

78,000

Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement (Note 4B)

1,000

(1,000)

Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement, shares

100,000

Exercise of prefunded warrants into shares (Note 3A)

2,000

(2,000)

Exercise of prefunded warrants into shares, shares

1,976,470

Exchange of warrants into shares (Note 3B)

$ 4,000

(4,000)

Exchange of warrants into shares, shares

3,593,203

Balance at Mar. 31, 2024

$ 27,000

$ 113,029,000

$ 78,000

$ 22,000

$ (112,780,000)

$ 376,000

Balance, shares at Mar. 31, 2024

26,756,369

[1]	Represents amount lower than $1.

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the period	$ (2,927)	$ (1,286)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4	4
Stock-based compensation	22	57
Issuance of restricted shares as compensation towards directors	78	5
Linkage difference on principal of loans from stockholders	(1)	2
Changes in assets and liabilities:
Increase in other current assets	(64)	(137)
Increase (decrease) in accounts payable	175	(13)
Increase (Decrease) in other current liabilities	(229)	55
Net cash used in operating activities	(2,942)	(1,313)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(59)
Net cash used in investing activities	(59)
Effect of exchange rate changes on cash and cash equivalents, and restricted cash	6	(5)
Change in cash and cash equivalents, and restricted cash	(2,995)	(1,318)
Cash and cash equivalents, and restricted cash at beginning of the period	4,502	2,331
Cash and cash equivalents, and restricted cash, end of period	1,507	1,013
Supplemental disclosure of cash flow activities:
Interest	28
(b) Non-cash activities:
Recognition of right for usage asset against a lease liability	$ 79

XML 18 R7.htm IDEA: XBRL DOCUMENT

GENERAL

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1 – GENERAL

A.	Glucotrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes. The Company is currently developing an Implantable Continuous Blood Glucose Monitor (“CBGM”) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM Product”).

B.	Liquidity and capital resources

	To date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are expected to require substantial additional expenditures. Therefore, the Company is dependent upon external sources for financing its operations. As of March 31, 2024, the Company has incurred accumulated deficit of $112,780. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods. As of March 31, 2024, the balance of cash and cash equivalents which amounted to $1,497,000 is insufficient for the Company to realize its business plans for the twelve-month period subsequent to the reporting period.

	Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
	During the year ended December 31, 2023, the Company raised net proceeds of $8,730 through completion of an underwritten public offering. In addition, during the year ended December 31, 2023, the Company entered into exchange agreement with certain shareholders under which warrants with down round protection feature have been exchanged into shares of common stock in order to improve its equity structure to enable the completion of a planned equity financing (see also Note 3A). Moreover, in April 2024, the Company raised net proceeds of $500,000 through completion of private placement transaction (see also Note 5A). The Company plans to finance its operations through the sale of equity and/or debt securities (including shelf registration statement on Form S-3 that was declared effective on September 27, 2021 by the Securities and Exchange Commission (“SEC”) and which allows the Company to register up to $90,000 of certain equity and/or debt securities of the Company through prospectus supplement). There can be no assurance that the Company will succeed in obtaining the necessary financing or generating sufficient revenues from sales of its Glucotrack CBGM Product, if any, in order to continue its operations as a going concern. The condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 19 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Basis of Presentation

	The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the SEC on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

	The results for the period of three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

B. Use of Estimates in the Preparation of Financial Statements

C. Principles of Consolidation

D. Cash and Cash Equivalents

E. Leases

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

F. Modification of equity-classified contracts

G. Basic and diluted loss per share

Basic loss per share is computed by dividing the loss for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)

(in thousands of US Dollars)

XML 20 R9.htm IDEA: XBRL DOCUMENT

SIGNIFICANT TRANSACTIONS

3 Months Ended

Mar. 31, 2024

Significant Transactions

SIGNIFICANT TRANSACTIONS

NOTE 3 - SIGNIFICANT TRANSACTIONS

A.	Exercise of pre-funded warrants

	On January 3, 2024, a number of 1,976,470 pre-funded warrants granted through underwritten public offering in April 2023 have been fully exercised into the same number of shares of Common Stock of the Company.

B.	Exchange Agreement

	On February 13, 2024, the Company entered into an Exchange Agreement with certain warrantholders (the “Holders”), pursuant to which the Company and the Holders agreed to exchange (the “Exchange”) warrants with down round protection feature exercisable to common shares (the “Warrants”) owned by the Holders for shares of Common Stock to be issued by the Company.

	On February 13, 2024, the Company closed the Exchange and issued to the Holders on February 15, 2024 an aggregate of 3,593,203 shares of Common Stock in exchange for 4,381,953 Warrants (the “Shares”).

	It was also agreed that the Holders will not, during the period (“Lock-Up Period”) (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided however that the Holder, during the Lock-Up Period, may (a) sell or contract to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than $0.80 per Share on any trading day with no limitation on volume. The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $1.00 per Share for five consecutive trading days. The Company accounted for the Exchange of the aforesaid warrants as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not recorded.

C.	Lease Agreement

	On February 19, 2024, the Company entered into Lease Agreement (the “Agreement”) with Tapsak Enterprises LLC dba Virginia Analytical (the “Landlord”) under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of $2.5 over a period of 3-years commencing March 1, 2024 through February 28, 2027 (the “Initial Lease Period”). A security deposit of $2.5 which represents a one month payment is held by the Landlord and will be returned to the Company at the end of the Initial Lease Period.

	In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the “Option Term”), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate which is determined as the comparable cost for similar property in the Front Royal, Virginia area.

	In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to usage asset equals to lease liability in total amount of $79. The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the estimated interest rate that the Company would be required to pay in order to borrow a similar amount for a similar period in order to obtain a similar amount on the date of first recognition of the lease (using a discount rate of 9.03%). As part of the lease term, the Company considered only the Initial Lease Period, as the exercise of the option to extend the period was not considered as reasonably certain.

Right of usage asset:

SCHEDULE OF RIGHT OF USAGE ASSET

	Premises
Cost
Balance as of January 1, 2024		-
Additions		79
Balance as of March 31, 2024		79
Accumulated amortization
Balance as of January 1, 2024		-
Additions		2
Balance as of March 31, 2024		2

Amortized cost as of March 31, 2024		77

Lease liability:

SCHEDULE OF LEASE LIABILITY

	Premises

Balance as of January 1, 2024		-
Additions		79
Interest expenses		1
Lease payments		(3	)

Balance as of March 31, 2024		77

Amounts recognized in statements of cash flow:

	Three months period ended March 31, 2024

Amortization of the right for usage asset		2
Interest expense in respect of lease liability		1
Repayment of principal in respect of lease liability		3

Total negative cash flows in respect of leasing for the period of three months ended March 31, 2024 are approximately $3.

Analysis of contractual payment dates of lease liability as of March 31, 2024:


Up to a year	$	30
Between 1-2 years		30
More than 2 years		28
Total (undiscounted)	$	88

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.)

(in thousands of US Dollars)

XML 21 R10.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 4 – COMMITMENTS AND CONTINGENT LIABILITIES

	A.	On March 4, 2004, the IIA provided Integrity Israel with a grant of approximately $93 (NIS 420,000), for its plan to develop a non-invasive blood glucose monitor (the “Development Plan”). Integrity Israel is required to pay royalties to the IIA at a rate ranging between 3-5% of the proceeds from the sale of the Company’s products arising from the Development Plan up to an amount equal to $93 plus interest at LIBOR from the date of grant. As to the replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of March 31, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $73 excluding interest. Such contingent obligation has no expiration date.

	B.	On October 7, 2022 (“the Closing Date”), the Company entered into an Intellectual Property Purchase Agreement (the “Agreement”) with Paul Goode, the Company’s Chief Executive Officer (the “Seller”), under which the parties agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, the Seller shall sell, assign, transfer, convey and deliver to the Company, all of the Seller’s right, title and interest in and to the following assets, properties and rights (collectively, the “Purchased Assets”):

	(a)	All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the “Conveyed Intellectual Property”); and

	(b)	All the goodwill relating to the Purchased Assets.

XML 22 R11.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 5 - SUBSEQUENT EVENTS

A.	Private Placement Agreement

There were no warrants issued and no commissions or brokerage fees paid in connection with the Offering.

B.	Reverse Stock Split

XML 23 R12.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation

A. Basis of Presentation

	The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the SEC on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

	The results for the period of three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Use of Estimates in the Preparation of Financial Statements

B. Use of Estimates in the Preparation of Financial Statements

Principles of Consolidation

C. Principles of Consolidation

Cash and Cash Equivalents

D. Cash and Cash Equivalents

Leases

E. Leases

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Modification of equity-classified contracts

F. Modification of equity-classified contracts

Basic and diluted loss per share

G. Basic and diluted loss per share

Basic loss per share is computed by dividing the loss for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding.

XML 24 R13.htm IDEA: XBRL DOCUMENT

SIGNIFICANT TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2024

Significant Transactions

SCHEDULE OF RIGHT OF USAGE ASSET

Right of usage asset:

SCHEDULE OF RIGHT OF USAGE ASSET

	Premises
Cost
Balance as of January 1, 2024		-
Additions		79
Balance as of March 31, 2024		79
Accumulated amortization
Balance as of January 1, 2024		-
Additions		2
Balance as of March 31, 2024		2

Amortized cost as of March 31, 2024		77

SCHEDULE OF LEASE LIABILITY

Lease liability:

SCHEDULE OF LEASE LIABILITY

	Premises

Balance as of January 1, 2024		-
Additions		79
Interest expenses		1
Lease payments		(3	)

Balance as of March 31, 2024		77

SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE

Amounts recognized in statements of cash flow:

	Three months period ended March 31, 2024

Amortization of the right for usage asset		2
Interest expense in respect of lease liability		1
Repayment of principal in respect of lease liability		3

SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY

Analysis of contractual payment dates of lease liability as of March 31, 2024:


Up to a year	$	30
Between 1-2 years		30
More than 2 years		28
Total (undiscounted)	$	88

XML 25 R14.htm IDEA: XBRL DOCUMENT

GENERAL (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
GENERAL (Details Narrative) - USD ($)	Apr. 30, 2024	Dec. 31, 2023	Mar. 31, 2024	Sep. 27, 2021
Subsequent Event [Line Items]
Accumulated deficit		$ 109,853,000	$ 112,780,000
Cash and cash equivalents		4,492,000	$ 1,497,000
Net proceeds		$ 8,730,000
Maximum [Member]
Subsequent Event [Line Items]
Debt securities				$ 90,000,000
Subsequent Event [Member] \| Private Placement [Member]
Subsequent Event [Line Items]
Net proceeds	$ 500,000,000

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

SCHEDULE OF RIGHT OF USAGE ASSET (Details) - Premises [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Property, Plant and Equipment [Line Items]
Beginning balance
Additions to operating lease right of use assets	79
Ending balance	79
Beginning balance
Additions to operating lease right of use assets accumulated amortization	2
Ending balance	2
Amortized cost	$ 77

XML 27 R16.htm IDEA: XBRL DOCUMENT

SCHEDULE OF LEASE LIABILITY (Details) $ in Thousands	3 Months Ended
SCHEDULE OF LEASE LIABILITY (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Significant Transactions
Beginning balance
Additions to operating lease liability	79
Interest expenses	1
Lease payments	(3)
Ending balance	$ 77

XML 28 R17.htm IDEA: XBRL DOCUMENT

SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Significant Transactions
Amortization of the right for usage asset	$ 2
Interest expense in respect of lease liability	1
Repayment of principal in respect of lease liability	$ 3

XML 29 R18.htm IDEA: XBRL DOCUMENT

SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Lessee, Lease, Description [Line Items]
Total (undiscounted)	$ 88
Up to a Year [Member]
Lessee, Lease, Description [Line Items]
Total (undiscounted)	30
Between 1-2 Years [Member]
Lessee, Lease, Description [Line Items]
Total (undiscounted)	30
More Than 2 Years [Member]
Lessee, Lease, Description [Line Items]
Total (undiscounted)	$ 28

XML 30 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT TRANSACTIONS (Details Narrative) - USD ($)				3 Months Ended
SIGNIFICANT TRANSACTIONS (Details Narrative) - USD ($)	Feb. 19, 2024	Feb. 13, 2024	Jan. 03, 2024	Mar. 31, 2024	Dec. 31, 2023
Monthly rental fee				$ 3,000
Operating lease liability				77,000
Discount rate	9.03%
Lease cost				$ 3,000
Exchange Agreement [Member]
Number of warrants issued		4,381,953
Lock-up period conditions		(a) sell or contract to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than $0.80 per Share on any trading day with no limitation on volume.
Share price		$ 1.00
Lease Agreements [Member]
Monthly rental fee	$ 2,500
Lessee term of contract	3 years
Security deposit	$ 2,500
Operating lease liability	$ 79,000
Prefunded Warrants [Member]
Pre-funded warrants			1,976,470,000
Common Stock [Member] \| Exchange Agreement [Member]
Number of common shares issued		3,593,203

XML 31 R20.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)			1 Months Ended	12 Months Ended
	Oct. 07, 2022 shares	Mar. 04, 2004 USD ($)	Jun. 20, 2023 shares	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 04, 2004 ILS (₪)
Loss Contingencies [Line Items]
Weighted Average Number of Shares, Restricted Stock			100,000
Other Research and Development Expense \| $				$ 131,000
Intellectual Property Purchase Agreement [Member] \| Common Stock [Member]
Loss Contingencies [Line Items]
Number of common shares issued	1,000,000
Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability \| $		$ 93			$ 73
Minimum [Member] \| Intellectual Property Purchase Agreement [Member] \| Common Stock [Member]
Loss Contingencies [Line Items]
Number of common shares issued	1,000,000
Commission as a percentage of aggregate sales price	1.50%
Minimum [Member] \| Intellectual Property Purchase Agreement [Member] \| Common Stock [Member] \| Trueup Shares [Member]
Loss Contingencies [Line Items]
Commission as a percentage of aggregate sales price	1.50%
Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability		$ 93				₪ 420,000
Israeli Innovation Authority [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty percentage		3.00%
Israeli Innovation Authority [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty percentage		5.00%

XML 32 R21.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)	Apr. 26, 2024	Apr. 22, 2024
Subsequent Event [Line Items]
Description of reverse stock split	the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors (the “Board”) to file a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.001 per share at a ratio between 1-for-5 and 1-for-30, to be effected at such time and date, if at all, as determined by the Board in its sole discretion (the “Reverse Stock Split”). On April 30, 2024, the Board approved the Reverse Stock Split.
Private Placement Agreement [Member]
Subsequent Event [Line Items]
Number of shares issued		396,825
Share price		$ 1.26
Aggregate gross proceeds		$ 500,000

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ƒ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end XML 34 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 66 141 1 true 21 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://glucotrack.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://glucotrack.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://glucotrack.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://glucotrack.com/role/StatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://glucotrack.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - GENERAL Sheet http://glucotrack.com/role/General GENERAL Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT TRANSACTIONS Sheet http://glucotrack.com/role/SignificantTransactions SIGNIFICANT TRANSACTIONS Notes 9 false false R10.htm 00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://glucotrack.com/role/CommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES Notes 10 false false R11.htm 00000011 - Disclosure - SUBSEQUENT EVENTS Sheet http://glucotrack.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 11 false false R12.htm 00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 12 false false R13.htm 00000013 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables) Sheet http://glucotrack.com/role/SignificantTransactionsTables SIGNIFICANT TRANSACTIONS (Tables) Tables http://glucotrack.com/role/SignificantTransactions 13 false false R14.htm 00000014 - Disclosure - GENERAL (Details Narrative) Sheet http://glucotrack.com/role/GeneralDetailsNarrative GENERAL (Details Narrative) Details http://glucotrack.com/role/General 14 false false R15.htm 00000015 - Disclosure - SCHEDULE OF RIGHT OF USAGE ASSET (Details) Sheet http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails SCHEDULE OF RIGHT OF USAGE ASSET (Details) Details 15 false false R16.htm 00000016 - Disclosure - SCHEDULE OF LEASE LIABILITY (Details) Sheet http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails SCHEDULE OF LEASE LIABILITY (Details) Details 16 false false R17.htm 00000017 - Disclosure - SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details) Sheet http://glucotrack.com/role/ScheduleOfAmountRecognizedOfOperatingLeaseDetails SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details) Details 17 false false R18.htm 00000018 - Disclosure - SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details) Sheet http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details) Details 18 false false R19.htm 00000019 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) Sheet http://glucotrack.com/role/SignificantTransactionsDetailsNarrative SIGNIFICANT TRANSACTIONS (Details Narrative) Details http://glucotrack.com/role/SignificantTransactionsTables 19 false false R20.htm 00000020 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Sheet http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Details http://glucotrack.com/role/CommitmentsAndContingentLiabilities 20 false false R21.htm 00000021 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://glucotrack.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://glucotrack.com/role/SubsequentEvents 21 false false All Reports Book All Reports form10-q.htm gctk-20240331.xsd gctk-20240331_cal.xml gctk-20240331_def.xml gctk-20240331_lab.xml gctk-20240331_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 39 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "GCTK", "nsuri": "http://glucotrack.com/20240331", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "gctk-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "gctk-20240331_cal.xml" ] }, "definitionLink": { "local": [ "gctk-20240331_def.xml" ] }, "labelLink": { "local": [ "gctk-20240331_lab.xml" ] }, "presentationLink": { "local": [ "gctk-20240331_pre.xml" ] } }, "keyStandard": 117, "keyCustom": 24, "axisStandard": 10, "axisCustom": 0, "memberStandard": 9, "memberCustom": 11, "hidden": { "total": 69, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 47, "http://glucotrack.com/20240331": 18 }, "contextCount": 66, "entityCount": 1, "segmentCount": 21, "elementCount": 241, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 251, "http://xbrl.sec.gov/dei/2024": 30, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://glucotrack.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://glucotrack.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://glucotrack.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://glucotrack.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://glucotrack.com/role/General", "longName": "00000007 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://glucotrack.com/role/SignificantTransactions", "longName": "00000009 - Disclosure - SIGNIFICANT TRANSACTIONS", "shortName": "SIGNIFICANT TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilities", "longName": "00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://glucotrack.com/role/SubsequentEvents", "longName": "00000011 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://glucotrack.com/role/SignificantTransactionsTables", "longName": "00000013 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)", "shortName": "SIGNIFICANT TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:ScheduleOfRightOfUsageAssetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:ScheduleOfRightOfUsageAssetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://glucotrack.com/role/GeneralDetailsNarrative", "longName": "00000014 - Disclosure - GENERAL (Details Narrative)", "shortName": "GENERAL (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "14", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R15": { "role": "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails", "longName": "00000015 - Disclosure - SCHEDULE OF RIGHT OF USAGE ASSET (Details)", "shortName": "SCHEDULE OF RIGHT OF USAGE ASSET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "15", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_custom_PremisesMember", "name": "GCTK:AdditionsToOperatingLeaseRightofUseAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:ScheduleOfRightOfUsageAssetTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_PremisesMember", "name": "GCTK:AdditionsToOperatingLeaseRightofUseAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:ScheduleOfRightOfUsageAssetTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails", "longName": "00000016 - Disclosure - SCHEDULE OF LEASE LIABILITY (Details)", "shortName": "SCHEDULE OF LEASE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:AdditionsToOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:DisclosureOfLeaseLiabilityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:AdditionsToOperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:DisclosureOfLeaseLiabilityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://glucotrack.com/role/ScheduleOfAmountRecognizedOfOperatingLeaseDetails", "longName": "00000017 - Disclosure - SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details)", "shortName": "SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:AmortizationOfRightForUsageAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:ScheduleOfOperatingLeaseLiabilityOfAmountRecognizedTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "GCTK:AmortizationOfRightForUsageAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:ScheduleOfOperatingLeaseLiabilityOfAmountRecognizedTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails", "longName": "00000018 - Disclosure - SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details)", "shortName": "SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "longName": "00000019 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)", "shortName": "SIGNIFICANT TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "GCTK:DisclosureOfLeaseLiabilityTableTextBlock", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-19", "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R20": { "role": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "From2023-06-012023-06-20", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-06-012023-06-20", "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "longName": "00000021 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "From2024-04-252024-04-26_us-gaap_SubsequentEventMember", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-252024-04-26_us-gaap_SubsequentEventMember", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity of Counterparty, Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": [ "r37", "r43" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r366" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r10", "r11", "r44", "r87", "r246", "r261", "r262" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r11", "r196", "r199", "r229", "r257", "r258", "r405", "r406", "r407", "r414", "r415", "r416", "r417" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r38" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r272", "r414", "r415", "r416", "r417", "r442", "r457" ] }, "GCTK_AdditionsToOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "AdditionsToOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Additions to operating lease liability", "documentation": "Additions to operating lease liability." } } }, "auth_ref": [] }, "GCTK_AdditionsToOperatingLeaseRightofUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "AdditionsToOperatingLeaseRightofUseAssets", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Additions to operating lease right of use assets", "documentation": "Additions to operating lease right of use assets." } } }, "auth_ref": [] }, "GCTK_AdditionsToOperatingLeaseRightofUseAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "AdditionsToOperatingLeaseRightofUseAssetsAccumulatedAmortization", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Additions to operating lease right of use assets accumulated amortization", "documentation": "Additions to operating lease right of use assets accumulated amortization." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "GCTK_AggregateSalesPriceOfUnitsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "AggregateSalesPriceOfUnitsPercentage", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commission as a percentage of aggregate sales price", "documentation": "Aggregate sales price of units percentage." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "GCTK_AmortizationOfRightForUsageAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "AmortizationOfRightForUsageAsset", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAmountRecognizedOfOperatingLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of the right for usage asset", "documentation": "Amortization of the right for usage asset." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r395" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r190" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r59", "r64", "r83", "r108", "r133", "r137", "r139", "r140", "r143", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r191", "r193", "r207", "r243", "r306", "r354", "r355", "r366", "r380", "r438", "r439", "r447" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r80", "r89", "r108", "r143", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r191", "r193", "r207", "r366", "r438", "r439", "r447" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r395" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "GCTK_BetweenOneYearToTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "BetweenOneYearToTwoYearsMember", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Between 1-2 Years [Member]", "documentation": "Between 1-2 Years [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r24", "r57", "r187", "r204", "r205", "r206" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r13", "r82", "r349" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r14" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash and cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r13", "r48", "r106" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Change in cash and cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r48" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r70", "r84", "r85", "r86", "r108", "r125", "r126", "r128", "r130", "r135", "r136", "r143", "r155", "r157", "r158", "r159", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r207", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r294", "r315", "r332", "r340", "r341", "r342", "r343", "r344", "r401", "r411", "r418" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r170" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Commitments and contingent liabilities (Note 4)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r33", "r60", "r244", "r293" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r54", "r147", "r148", "r345", "r433", "r435" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r370", "r371", "r372", "r374", "r375", "r376", "r377", "r414", "r415", "r417", "r442", "r456", "r457" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r36", "r294" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r36", "r294", "r312", "r457", "r458" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock of $ 0.001 par value (\u201cCommon Stock\u201d): 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 26,756,369 and 20,892,193 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r36", "r245", "r366" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Comprehensive loss for the period", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r12", "r92", "r94", "r99", "r238", "r252", "r253" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r25", "r350" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONTRACTUAL PAYMENT LEASE LIABILITY", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r403", "r413" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecurities", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r142", "r241", "r242", "r368", "r369" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r133", "r138", "r140", "r354", "r355" ] }, "GCTK_DisclosureOfLeaseLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "DisclosureOfLeaseLiabilityTableTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LEASE LIABILITY", "documentation": "Disclosure of lease liability [Table Text Block]" } } }, "auth_ref": [] }, "GCTK_DisclosureSignificantTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "DisclosureSignificantTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Significant Transactions", "verboseLabel": "Schedule Of Lease Liability", "terseLabel": "Schedule Of Amount Recognized Of Operating Lease" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r394" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r392", "r394", "r395" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r393" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r381" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r394" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r394" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r396" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r384" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic net loss per common stock", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r100", "r114", "r115", "r116", "r117", "r118", "r119", "r123", "r125", "r128", "r129", "r130", "r132", "r185", "r189", "r202", "r203", "r239", "r254", "r351" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted net loss per common stock", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r100", "r114", "r115", "r116", "r117", "r118", "r119", "r125", "r128", "r129", "r130", "r132", "r185", "r189", "r202", "r203", "r239", "r254", "r351" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r16", "r17", "r131" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r445" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r387" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r383" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r383" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r400" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r383" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r397" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r395" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r383" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r383" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r383" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r383" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r398" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r78", "r95", "r96", "r97", "r109", "r110", "r111", "r113", "r118", "r120", "r122", "r134", "r144", "r145", "r146", "r171", "r180", "r181", "r182", "r183", "r184", "r186", "r188", "r189", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r208", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r229", "r251", "r257", "r258", "r259", "r272", "r332" ] }, "GCTK_ExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ExchangeAgreementMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exchange Agreement [Member]", "documentation": "Exchange Agreement [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "GCTK_FinancingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "FinancingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance expenses (income), net", "documentation": "Financing income expense net.", "label": "FinancingIncomeExpenseNet" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r46", "r317" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r408" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r408" ] }, "GCTK_IntellectualPropertyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "IntellectualPropertyPurchaseAgreementMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intellectual Property Purchase Agreement [Member]", "documentation": "Intellectual Property Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r102", "r104", "r105" ] }, "GCTK_InterstExpenseOnLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "InterstExpenseOnLeaseLiability", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAmountRecognizedOfOperatingLeaseDetails", "http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Interest expenses", "verboseLabel": "Interest expense in respect of lease liability", "documentation": "Interst expense on lease liability." } } }, "auth_ref": [] }, "GCTK_IsraeliInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "IsraeliInnovationAuthorityMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Israeli Innovation Authority [Member]", "documentation": "Israeli Innovation Authority [Member]" } } }, "auth_ref": [] }, "GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of restricted shares as compensation towards directors", "documentation": "Issuance of restricted shares as compensation to the board of directors.", "label": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" } } }, "auth_ref": [] }, "us-gaap_LeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAgreementsMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease Agreements [Member]", "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset." } } }, "auth_ref": [ "r23", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r228", "r402" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r228", "r402" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r223", "r365" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "GCTK_LessThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "LessThanOneYearMember", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Up to a Year [Member]", "documentation": "Up to a Year [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r228" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r222", "r228" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r221" ] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r364" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Total (undiscounted)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r226" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lessee term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r446" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r28", "r29", "r30", "r31", "r32", "r33", "r34", "r108", "r143", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r192", "r193", "r194", "r207", "r292", "r352", "r380", "r438", "r447", "r448" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r42", "r61", "r248", "r366", "r412", "r424", "r444" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r30", "r81", "r108", "r143", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r192", "r193", "r194", "r207", "r366", "r438", "r447", "r448" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current Liabilities" } } }, "auth_ref": [] }, "GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Linkage difference on principal of loans from stockholders", "documentation": "Linkage difference on principal of loans from stockholders ." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "GCTK_LockUpPeriodDescription": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "LockUpPeriodDescription", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lock-up period conditions", "documentation": "Lock up period description." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r150", "r151", "r154", "r178", "r357", "r436", "r437" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r149", "r150", "r151", "r154", "r178", "r357", "r436", "r437" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r150", "r151", "r152", "r153", "r173", "r178", "r206", "r235", "r255", "r256", "r263", "r284", "r285", "r335", "r336", "r337", "r338", "r339", "r346", "r347", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r367", "r440", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r150", "r151", "r152", "r153", "r173", "r178", "r206", "r235", "r255", "r256", "r263", "r284", "r285", "r335", "r336", "r337", "r338", "r339", "r346", "r347", "r356", "r358", "r359", "r360", "r361", "r362", "r367", "r440", "r449", "r450", "r451", "r452", "r453", "r454" ] }, "GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ModificationOfEquityClassifiedContractsPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Modification of equity-classified contracts", "documentation": "Modification Of Equity Classified Contracts [Policy Text Block]" } } }, "auth_ref": [] }, "GCTK_MoreThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "MoreThanTwoYearsMember", "presentation": [ "http://glucotrack.com/role/ScheduleOfContractualPaymentLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "More Than 2 Years [Member]", "documentation": "More Than 2 Years [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r103" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r48", "r49", "r50" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/StatementsOfCashFlows", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Loss", "label": "Loss for the period", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r45", "r50", "r62", "r79", "r90", "r93", "r97", "r108", "r112", "r114", "r115", "r116", "r117", "r118", "r121", "r122", "r127", "r143", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r185", "r189", "r203", "r207", "r250", "r314", "r330", "r331", "r378", "r438" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(b) Non-cash activities:" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r63", "r353", "r419", "r420", "r421", "r422", "r423" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Recognition of right for usage asset against a lease liability", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r224", "r365" ] }, "GCTK_OperatingLeaseCostRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "OperatingLeaseCostRightOfUseAsset", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Operating lease cost right of use asset.", "label": "OperatingLeaseCostRightOfUseAsset" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r219" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current (Note 3C)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r219" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, non-current (Note 3C)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r219" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAmountRecognizedOfOperatingLeaseDetails", "http://glucotrack.com/role/ScheduleOfLeaseLiabilityDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease payments", "totalLabel": "Repayment of principal in respect of lease liability", "label": "Monthly rental fee", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r220", "r225" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset, net (Note 3C)", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r218" ] }, "GCTK_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Operating lease right of use asset accumulated amortization.", "label": "OperatingLeaseRightOfUseAssetAccumulatedAmortization" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Amortized cost", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r409" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://glucotrack.com/role/General" ], "lang": { "en-us": { "role": { "label": "GENERAL", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r26", "r58", "r264", "r265" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r88", "r366" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r251" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r7", "r8", "r91", "r94", "r98", "r118", "r208", "r209", "r214", "r237", "r251", "r405", "r406" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income:" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r366" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loans from stockholders", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r394" ] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r441" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r47" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r388" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r390" ] }, "GCTK_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "PrefundedWarrantsMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]", "documentation": "Prefunded Warrants [Member]" } } }, "auth_ref": [] }, "GCTK_PremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "PremisesMember", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Premises [Member]", "documentation": "Premises [Member]" } } }, "auth_ref": [] }, "GCTK_PrivatePlacementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "PrivatePlacementAgreementMember", "presentation": [ "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement Agreement [Member]", "documentation": "Private Placement Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r101" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r227" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r227" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r227", "r240", "r249", "r366" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r53", "r227" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r150", "r151", "r152", "r153", "r172", "r173", "r175", "r176", "r177", "r178", "r206", "r233", "r234", "r235", "r255", "r256", "r263", "r284", "r285", "r335", "r336", "r337", "r338", "r339", "r346", "r347", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r367", "r372", "r434", "r440", "r443", "r450", "r451", "r452", "r453", "r454" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r150", "r151", "r152", "r153", "r172", "r173", "r175", "r176", "r177", "r178", "r206", "r233", "r234", "r235", "r255", "r256", "r263", "r284", "r285", "r335", "r336", "r337", "r338", "r339", "r346", "r347", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r367", "r372", "r434", "r440", "r443", "r450", "r451", "r452", "r453", "r454" ] }, "GCTK_ReceiptsOnAccountOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ReceiptsOnAccountOfShares", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Receipts on account of shares", "documentation": "Receipts on account of shares." } } }, "auth_ref": [] }, "GCTK_ReceiptsOnAccountOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ReceiptsOnAccountOfSharesMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Receipts on Account of Shares [Member]", "documentation": "Receipts on Account of Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r179", "r348", "r354", "r455" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r65", "r404", "r410" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r39", "r55", "r247", "r260", "r262", "r271", "r295", "r366" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r78", "r109", "r110", "r111", "r113", "r118", "r120", "r122", "r144", "r145", "r146", "r180", "r181", "r182", "r183", "r184", "r186", "r188", "r189", "r195", "r197", "r198", "r200", "r201", "r216", "r217", "r257", "r259", "r272", "r457" ] }, "GCTK_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "RoyaltyPercentage", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Royalty percentage", "documentation": "Royalty percentage." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "GCTK_ScheduleOfOperatingLeaseLiabilityOfAmountRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ScheduleOfOperatingLeaseLiabilityOfAmountRecognizedTableTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF AMOUNT RECOGNIZED OF OPERATING LEASE", "documentation": "Schedule Of Operating Lease Liability Of Amount Recognized [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://glucotrack.com/role/ScheduleOfRightOfUsageAssetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5", "r227" ] }, "GCTK_ScheduleOfRightOfUsageAssetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "ScheduleOfRightOfUsageAssetTableTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF RIGHT OF USAGE ASSET", "documentation": "Schedule of right of usage asset [Table Text Block]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r382" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r386" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r404" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r385" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r391" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling and marketing expenses", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r51", "r107" ] }, "GCTK_SignificantTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "SignificantTransactionsTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactions" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT TRANSACTIONS", "documentation": "Significant Transactions [Text Block]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r389" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r70", "r84", "r85", "r86", "r108", "r125", "r126", "r128", "r130", "r135", "r136", "r143", "r155", "r157", "r158", "r159", "r162", "r163", "r165", "r166", "r167", "r168", "r169", "r207", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r294", "r315", "r332", "r340", "r341", "r342", "r343", "r344", "r401", "r411", "r418" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r36", "r40", "r41", "r78", "r95", "r96", "r97", "r109", "r110", "r111", "r113", "r118", "r120", "r122", "r134", "r144", "r145", "r146", "r171", "r180", "r181", "r182", "r183", "r184", "r186", "r188", "r189", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r208", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r229", "r251", "r257", "r258", "r259", "r272", "r332" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r109", "r110", "r111", "r134", "r217", "r236", "r266", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r313", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r373" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r109", "r110", "r111", "r134", "r141", "r217", "r236", "r266", "r283", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r313", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r373" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exchange of warrants into shares, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r21", "r36", "r40", "r55", "r164" ] }, "GCTK_StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "StockIssuedDuringPeriodSharesExerciseofPrefundedWarrantsIntoShares", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of prefunded warrants into shares, shares", "documentation": "Exercise of prefunded warrants into shares ,shares." } } }, "auth_ref": [] }, "GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement, shares", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of common shares issued", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r35", "r36", "r55", "r267", "r332", "r341" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as compensation towards directors, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r7", "r55" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre-funded warrants", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r35", "r36", "r55", "r174" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exchange of warrants into shares (Note 3B)", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r36", "r40", "r41", "r55" ] }, "GCTK_StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of prefunded warrants into shares (Note 3A)", "documentation": "Exercise of prefunded warrants into shares." } } }, "auth_ref": [] }, "GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement (Note 4B)", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate gross proceeds", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r35", "r36", "r55", "r272", "r332", "r341", "r379" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as compensation towards directors", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r7", "r35", "r36", "r55" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r22", "r35", "r36", "r55" ] }, "GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted shares to be issued as compensation towards directors", "documentation": "Stock to be issued during period value restricted stock award gross." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r36", "r40", "r41", "r52", "r296", "r312", "r333", "r334", "r366", "r380", "r412", "r424", "r444", "r457" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r56" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r215", "r231" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r215", "r231" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r215", "r231" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r215", "r231" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r215", "r231" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://glucotrack.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r230", "r232" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow activities:" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "GCTK_TrueupSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240331", "localname": "TrueupSharesMember", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Trueup Shares [Member]", "documentation": "Trueup Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r190" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates in the Preparation of Financial Statements", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r18", "r19", "r20", "r66", "r67", "r68", "r69" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common stock outstanding used in computing diluted net loss per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r124", "r130" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common stock outstanding used in computing basic net loss per share", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r123", "r130" ] }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesRestrictedStock", "presentation": [ "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares, Restricted Stock", "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends." } } }, "auth_ref": [ "r15" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r399" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r355": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r356": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r357": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r358": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r360": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r361": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r362": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r363": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r364": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r366": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r367": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r368": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r369": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r370": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r379": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r380": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r382": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r387": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r388": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r389": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r390": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r391": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r401": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Subparagraph": "(a)", "Publisher": "SEC" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 40 0001493152-24-019999-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-019999-xbrl.zip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